Financial Performance - The company expects a net profit loss between 58 million and 83 million yuan for the fiscal year 2025, compared to a loss of 66.62 million yuan in the same period last year [4]. - Revenue is projected to be between 1.01 billion and 1.061 billion yuan, reflecting a year-on-year change of -2% to 3% from 1.0309264 billion yuan [4]. - The impact of non-recurring gains and losses on net profit is estimated to be approximately 8.7 million yuan, down from 10.06 million yuan in the previous year [6]. Market Conditions - The company faces increased competition in its industry, leading to a contraction in gross profit margins for some products [6]. - The benefits from the application expansion of new products have not yet been fully realized, contributing to the overall performance pressure [6]. Audit and Reporting - The financial data in the earnings forecast has not been audited by the accounting firm, and the company has communicated with them regarding the forecast without major discrepancies [5]. - The specific financial data will be detailed in the company's 2025 annual report, urging investors to make cautious decisions and be aware of investment risks [7].

Financial Projections - The estimated net profit for 2025 is projected to be between -3 million and -2 million CNY, a significant decrease compared to the previous year's profit of 14.77 million CNY[5] - The net profit after deducting non-recurring gains and losses is expected to be between -8 million and -7 million CNY, showing an increase compared to the previous year's loss of 15.68 million CNY[5] - The decrease in net profit is primarily due to a significant reduction in non-recurring gains and losses, estimated to be around 5 million CNY for 2025[7] Market Outlook - The company anticipates increased demand in the vehicle emission testing equipment market due to stricter regulatory requirements from the Ministry of Ecology and Environment[8] - The change in the scope of consolidation due to the acquisition of a subsidiary is also a contributing factor to the expected financial performance[8] Financial Reporting - The financial data in this earnings forecast has not been audited by a registered accounting firm[6] - The specific financial data for the 2025 fiscal year will be detailed in the company's annual report[9] - The company emphasizes the importance of timely information disclosure in accordance with relevant laws and regulations[9] Investor Guidance - Investors are advised to make cautious decisions and be aware of investment risks[9] - The earnings forecast period is from January 1, 2025, to December 31, 2025[3]

2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或者重 大遗漏。 一、本期业绩预计情况 1.业绩预告期间：2025 年 1 月 1 日-2025 年 12 月 31 日 证券代码：000026 200026 证券简称：飞亚达 飞亚达 B 公告编号：2026-003 飞亚达精密科技股份有限公司 2.业绩预告情况：预计净利润为正值且属于同向下降情形 | 项目 | 本报告期 | | | 上年同期 | | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | 盈利：7,600 | 万元–9,800 | 万元 | 盈利：22,035.02 | 万元 | | | | 比上年同期下降：65.51%-55.53% | | | | | | | 扣除非经常性损 益后的净利润 | 盈利：7,200 | 万元–9,400 | 万元 | 盈利：20,872.83 | 万元 | | | | 比上年同期下降：65.51%-54.97% | | | | | | | 基本每股收益 | 盈利：0.1873 | 元 ...

Financial Performance - The company expects a net loss of between 170 million and 240 million yuan for the fiscal year 2025, compared to a loss of 156.30 million yuan in the same period last year[3] - The net loss after deducting non-recurring gains and losses is projected to be between 177.50 million and 247.50 million yuan, compared to a loss of 199.54 million yuan in the previous year[3] - The company anticipates a reduction of approximately 35.73 million yuan in non-recurring gains and losses, primarily due to a significant decrease in government subsidies[6] Investment and Development - The primary reason for the loss is the ongoing investment in innovative drug development, with significant R&D and management expenses due to prior fixed asset investments[5] - The clinical trial for the innovative hepatitis B treatment drug GST-HG141 has enrolled 526 participants, meeting the planned target, with full enrollment expected by mid-February 2026[5] Asset Management - The company is conducting impairment tests on intangible assets, inventory, and fixed assets, with provisions for impairment being made[6] Caution for Investors - The final financial data for the fiscal year 2025 will be disclosed in the annual report, and investors are advised to exercise caution[7]

Financial Projections - The company expects a net profit in the range of -50,000 to -25,000 thousand yuan for the year 2025, representing a decrease of 6.29% to an increase of 46.86% compared to the previous year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -56,000 and -28,000 thousand yuan, reflecting a decrease of 21.17% to an increase of 39.41% year-over-year[5]. - The basic earnings per share is estimated to be between -0.2901 and -0.1451 yuan, compared to -0.2685 yuan in the previous year[5]. Operational Challenges - The decline in operating income and gross profit is attributed to intensified market competition and extended project settlement cycles[7]. Impairment and Tax Assets - The company plans to recognize impairment losses on accounts receivable, contract assets, and long-term receivables, with specific amounts pending audit confirmation[8]. - The company has terminated the recognition of certain deferred tax assets based on the principle of prudence[8]. Financial Reporting - The financial data presented is preliminary and subject to final confirmation in the 2025 annual report, highlighting investment risks[10].

证券代码：002068 证券简称：黑猫股份 公告编号：2026-001 江西黑猫炭黑股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日 二、与会计师事务所沟通情况 本次业绩预告未经会计师事务所预审计。公司已就本次业绩预告与年报审计会计 师事务所进行了预沟通，公司与会计师事务所在业绩预告方面不存在分歧。 三、业绩变动原因说明 报告期内，公司主要产品受行业多重因素叠加影响，主要原料煤焦油价格全年波 动剧烈且整体承压，成本端压力持续凸显；叠加下游轮胎行业影响，炭黑市场需求支 撑不足，行业供需格局承压，产品价格与成本出现倒挂，导致公司主要产品利润空间 被大幅挤压，盈利水平下滑。后续公司将着力强化科技创新驱动，深化成本管控与生 产运营效率提升，修复整体毛利，稳步改善经营状况。 四、其他相关说明 本次业绩预告是公司财务部门初步测算的结果，未经会计师事务所审计，具体财 务数据将在公司2025年度报告中详细披露，敬请广大投资者注意投资风险。 证券代码：00206 ...

证券代码：002975 证券简称：博杰股份 公告编号：2026-014 珠海博杰电子股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 单位：万元 | 项 目 | 本会计年度 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | 13,000.00 | | ～ | 16,000.00 | 2,225.42 | | | 比上年同期增长 | 484.16% | ～ | 618.97% | | | 扣除非经常性损益后的净利润 | | 8,000.00 | ～ | 11,000.00 | 894.37 | | | 比上年同期增长 | 794.48% | ～ | 1,129.92% | | | 基本每股收益（元/股） | | 0.85 | ～ | 1.05 | 0.16 | | 营业收入 | | 170,000.00 | ～ | 195,000 ...

证券代码：600208 证券简称：衢州发展 公告编号：2026-004 衢州信安发展股份有限公司 2025 年度业绩预减公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 业绩预告的具体适用情形：实现盈利，且净利润与上年同期相比 下降 50%以上。 预计2025年度实现归属于母公司所有者的净利润约20,000万元， 与上年同期相比，将减少 81,574 万元，同比减少 80.31%。 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益 的净利润约 54,000 万元，与上年同期（法定披露数据）相比，预计 减少 121,190 万元，同比减少 69.18%。 二、上年同期经营业绩和财务状况 一、本期业绩预告情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 经财务部门初步测算，预计 2025 年年度实现归属于母公司所有 者的净利润约 20,000 万元，与上年同期（法定披露数据）相比，预 计减少 81,574 万元，同比减少 80.31%。 ...

Financial Performance - The company expects a net loss of 150 million yuan for the fiscal year 2025, compared to a net loss of 190.98 million yuan in the same period last year[3] - The loss attributable to shareholders is projected to be 168 million yuan after deducting non-recurring gains and losses, an increase from 203.85 million yuan in the previous year[3] - Basic earnings per share are expected to be a loss of 0.11 yuan per share, compared to a loss of 0.14 yuan per share in the prior year[3] Factors Affecting Loss - The increase in net loss is attributed to foreign exchange losses due to currency fluctuations, which negatively impacted net profit[5] - The company has made provisions for potential additional losses related to arbitration concerning its natural gas power generation project in Mexico[5] - Impairment provisions have been made for long-term equity investments and other assets due to identified risks[5] Financial Reporting - The financial data presented is preliminary and will be detailed in the company's annual report for 2025[7] - The company has communicated with its accounting firm regarding the earnings forecast, with no significant discrepancies reported[4] - The earnings forecast period is from January 1, 2025, to December 31, 2025[3] - Investors are advised to exercise caution and consider investment risks based on the preliminary nature of the financial data[7]

2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 （1）以区间数进行业绩预告的 | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | | 盈利：28,400 万元–37,700 | | 万元 | 盈利：64,674 | 万元 | | | | 比上年同期下降：56.09%–41.71% | | | | | | 扣除非经常性损益 后的净利润 | | 盈利：36,200 | 万元–46,000 | 万元 | 盈利：25,354 | 万元 | | | | 比上年同期增长：42.78%–81.43% | | | | | | 基本每股收益 | | 盈利：0.1936 元/股 | 元/股–0.2569 | | 盈利：0.4408 | 元/股 | 二、与会计师事务所沟通情况 证券代码：002399 证券简称：海普瑞 公告编号：2026-001 深圳市海普瑞药业集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性 ...